Prescient Therapeutics (FRA:UDD) Total Operating Expense: €7.44 Mil (TTM As of Dec. 2025)


FRA:UDD Prescient Therapeutics Ltd FRA:UDD
22 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Prescient Therapeutics Total Operating Expense?

Prescient Therapeutics FRA:UDD +1.64% 22 Total Operating Expense is €7.44 Mil as of Dec. 2025. GuruFocus rates FRA:UDD with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Prescient Therapeutics's Total Operating Expense for the six months ended in Dec. 2025 was €2.92 Mil. Prescient Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €7.44 Mil.

Prescient Therapeutics Total Operating Expense Related Terms

Prescient Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Total Operating Expense Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 4.72 6.13 6.72 6.72

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 3.06 2.35 4.52 2.92
FRA:UDD
22GF Score
Prescient Therapeutics Ltd FRA:UDD
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prescient Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €7.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €7.44 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Total Operating Expense of €7.44 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Total Operating Expense too high?
Prescient Therapeutics' current Total Operating Expense is €7.44 Mil. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' Total Operating Expense compare to VRTX and REGN?
Prescient Therapeutics' Total Operating Expense of €7.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Total Operating Expense is €7.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Total Operating Expense of €7.44 Mil. The current Total Operating Expense is €7.44 Mil. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Total Operating Expense is €7.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score

Get the complete analysis for FRA:UDD

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price